Tositumomab I-131: all 23 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOPCompletedNCT01868035Phase 2Results posted
- Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade HistologiesCompletedNCT01224821Phase 2Results posted
- Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's LymphomaCompletedNCT00996996Phase 2Results posted
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's LymphomaCompletedNCT00989664Phase 2Results posted
- Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive HistologyCompletedNCT00950755Phase 2Results posted
- Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 AntibodyCompletedNCT00938041Phase 2Results posted
- Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 TositumomabCompletedNCT00933335Phase 2Results posted
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation TherapyTerminatedNCT00490490Phase 2Results posted
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCLCompletedNCT00490009Phase 2Results posted
- A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaTerminatedNCT00479167Phase 2Results posted
- Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First RemissionCompletedNCT00476047Phase 2Results posted
- Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and BexxarTerminatedNCT00475332Phase 2Results posted
- Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins LymphomaCompletedNCT00268983Phase 3Results posted
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaCompletedNCT00135200Phase 2Results posted
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow InvolvementCompletedNCT00992758Phase 1
- Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous TransplantCompletedNCT00434629Phase 1
- Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 TositumomabCompletedNCT00062894Phase 1/2
- Expanded Access Study of Iodine-131 Anti-B1 AntibodyStatus unknownNCT00022958Not applicable
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell LymphomaCompletedNCT00022945Phase 2
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOPStatus unknownNCT00022932Phase 2
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow InvolvementStatus unknownNCT00022906Phase 1
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's LymphomaStatus unknownNCT00022893Not applicable
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic LeukemiaStatus unknownNCT00022880Phase 1